Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.1K
Experimental RNAi02:15

Experimental RNAi

8.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K
RNA Interference01:23

RNA Interference

28.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Types of RNA01:23

Types of RNA

73.5K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
73.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MAPK-activated protein kinase 2 orchestrates memory T-cell inflation in cytomegalovirus infection.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.

Nature communications·2026
Same author

GSH-Responsive Nanoparticles Enhance Hepatocellular Carcinoma Immunotherapy Through Synergistic Effects of Cuproptosis and PI3K Inhibitor Combination.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Reversing Cuproptosis Tolerance with Twinborn Metallic Polymer Nanoparticles for Enhancing Efficacy of Chemo-Immunotherapy.

ACS nano·2026
Same author

Bone-Targeted Nanoparticles Enable Metabolic Reprogramming via cGAS Lactylation Suppression to Restore Chemosensitivity and Antitumor Immunity in Osteosarcoma.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Cytosol-Targeting Delivery of Non-Nucleotide STING Agonist Achieves Inhalable Nanoparticle-Based Anthrax Vaccine.

Advanced materials (Deerfield Beach, Fla.)·2026

Related Experiment Video

Updated: Mar 7, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.5K

Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents.

Haihua Xiao1, Ruogu Qi1, Ting Li1

  • 1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States.

Journal of the American Chemical Society
|February 7, 2017
PubMed
Summary

Platinum(II) anticancer agents rapidly platinate siRNA, reducing RNA interference (RNAi) efficiency. A novel micelle strategy co-delivering platinum(IV) and siRNA maximizes BCL-2 mRNA suppression and enhances anticancer effects.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 7, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.5K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K

Area of Science:

  • Biochemistry and Molecular Biology
  • Nanotechnology in Medicine
  • Cancer Therapeutics

Background:

  • RNA interference (RNAi) combined with platinum-based chemotherapy faces challenges due to platinum-induced siRNA damage.
  • Platinum(II) agents form adducts with guanosine residues in siRNA, impairing RNAi efficacy at typical experimental concentrations.
  • Platinum(IV) analogues avoid direct siRNA platination but show lower cellular uptake and potency.

Purpose of the Study:

  • To investigate the impact of platinum(II) agents on siRNA integrity and RNAi efficiency.
  • To develop and evaluate a novel drug delivery system for combined RNAi and platinum chemotherapy.
  • To optimize the synergistic delivery of BCL-2 siRNA and platinum analogues for enhanced cancer treatment.

Main Methods:

  • Spectroscopic characterization to analyze platinum-siRNA adduct formation.
  • Development of biodegradable mPEG-b-PCL-b-PLL micelles for co-delivery of siRNA and platinum agents.
  • In vitro assessment of BCL-2 mRNA suppression, intracellular platinum levels, DNA adduct formation, apoptosis induction, and antiproliferative activity.

Main Results:

  • Platinum(II) agents rapidly platinated BCL-2 siRNA, significantly reducing its ability to suppress mRNA levels.
  • Co-encapsulation of BCL-2 siRNA and platinum(IV) analogues in micelles achieved maximal BCL-2 mRNA suppression (<10%).
  • The micelle strategy enhanced intracellular platinum levels (~4x), DNA adducts (>5x), apoptosis (~4x), and antiproliferative activity (10-100x).

Conclusions:

  • Standard in vitro concentrations of platinum(II) agents are detrimental to siRNA function in combination therapies.
  • A micelle-based co-delivery system using platinum(IV) analogues and siRNA represents a promising strategy for synergistic cancer therapy.
  • This generalizable approach can maximize the synergy between RNAi and platinum-based agents for therapeutic applications and drug screening.